CA
CORT icon

Clearstead Advisors’s Corcept Therapeutics CORT Stock Holding History

Clearstead Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37K Buy
+426
New +$25.7K ﹤0.01% 1599
2026
Q1 		– Sell
-7
Closed -$244 – 2374
2025
Q4 		$244 Sell
7
-304
-98% -$23.9K ﹤0.01% 2397
2025
Q3 		$25.8K Buy
311
+193
+164% +$14K ﹤0.01% 1526
2025
Q2 		$8.66K Buy
+118
New +$8.55K ﹤0.01% 1929

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Clearstead Advisors's CORT Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 426 shares worth $37K. The stake represents ﹤0.01% of the portfolio and ranks #1599 among its holdings. This is a return to the name: Clearstead Advisors previously reported a position in CORT as recently as Q4 2025.

Clearstead Advisors first reported a position in CORT in Q2 2025 and has held it in 4 quarters since. 422 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Clearstead Advisors held 426 shares of Corcept Therapeutics worth $37K as of Q2 2026.
  • Corcept Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1599 holding.
  • Clearstead Advisors first reported a position in Corcept Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.